Cargando…
Effect of MMX(®) mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials
BACKGROUND: MMX(®) mesalamine is a once daily oral 5-aminosalicylic acid formulation, effective in induction and maintenance of ulcerative colitis remission. Patients on long-term mesalamine maintenance may occasionally require concomitant antibiotic treatment for unrelated infections. AIM: To evalu...
Autores principales: | Pierce, David, Corcoran, Mary, Martin, Patrick, Barrett, Karen, Inglis, Susi, Preston, Peter, Thompson, Thomas N, Willsie, Sandra K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029757/ https://www.ncbi.nlm.nih.gov/pubmed/24868146 http://dx.doi.org/10.2147/DDDT.S55373 |
Ejemplares similares
-
Once-daily MMX mesalamine for the treatment of mild-to-moderate ulcerative colitis
por: Kedia, Prashant, et al.
Publicado: (2007) -
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine
por: Nanda, Kavinderjit, et al.
Publicado: (2012) -
Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine
por: Zandman, Daniel B, et al.
Publicado: (2009) -
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. [Corrigendum]
por: Nanda, K, et al.
Publicado: (2013) -
The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX(®) formulated delayed-release mesalamine
por: Yarlas, Aaron, et al.
Publicado: (2014)